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Stroke is a devastating disorder that causes significant mor-bidity and mortality worldwide. Little progress has been 
made in finding new remedies for patients beyond the thera-
peutic window of tPA (tissue-type plasminogen activator).1,2 
Autoimmune responses can occur when lymphocytes encoun-
ter brain antigens in the periphery or within the brain.3–5 Several 
studies during the past decade have attempted to determine how 
autoimmune responses to brain antigens can emerge in patients 
with stroke and in rodents after middle cerebral artery occlu-
sion (MCAO).4–6 For example, both antibodies and circulating 
T cells can become sensitized to brain antigens, such as MBP 
(myelin basic protein) and related peptides,7–9 whereas other 
studies failed to demonstrate this.3,5 Therefore, development of 
autoimmunity to brain antigens in stroke remains debated.
Autoimmune responses are highly influenced by CD4+ 
T cells.10,11 In autoimmune diseases, the anatomic locations 
for activation of autoreactive T cells may include peripheral 
lymphoid organs, such as the spleen or cervical lymph nodes, 
as well as the central nervous system (CNS). Yet the timing, 
anatomic location, and antigen-presenting cells (APCs) pos-
sibly involved in the trigger of autoimmunity in stroke remain 
ill defined. Similarly, it is debated whether possible develop-
ment of autoimmune responses can impact stroke outcomes. 
Although it has been reported that the adoptive transfer of lym-
phocytes against myelin antigen exacerbates stroke lesions12,13 
and that proinflammatory lymphocytes are detrimental during 
early stage of ischemic brain injury,14 it is not known whether 
neuroantigen-specific T cells arising in vivo after stroke may 
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Background and Purpose—Autoimmune responses can occur when antigens from the central nervous system are presented 
to lymphocytes in the periphery or central nervous system in several neurological diseases. However, whether autoimmune 
responses emerge after brain ischemia and their impact on clinical outcomes remains controversial. We hypothesized that 
brain ischemia facilitates the genesis of autoimmunity and aggravates ischemic brain injury.
Methods—Using a mouse strain that harbors a transgenic T-cell receptor to a central nervous system antigen, MOG35-55 
(myelin oligodendrocyte glycoprotein) epitope (2D2), we determined the anatomic location and involvement of antigen-
presenting cells in the development of T-cell reactivity after brain ischemia and how T-cell reactivity impacts stroke 
outcome. Transient middle cerebral artery occlusion and photothrombotic stroke models were used in this study. We also 
quantified the presence and status of T cells from brain slices of ischemic patients.
Results—By coupling transfer of labeled MOG35-55-specific (2D2) T cells with tetramer tracking, we show an expansion in 
reactivity of 2D2 T cells to MOG91-108 and MOG103-125 in transient middle cerebral artery occlusion and photothrombotic 
stroke models. This reactivity and T-cell activation first occur locally in the brain after ischemia. Also, microglia act 
as antigen-presenting cells that effectively present MOG antigens, and depletion of microglia ablates expansion of 
2D2 reactive T cells. Notably, the adoptive transfer of neuroantigen-experienced 2D2 T cells exacerbates Th1/Th17 
responses and brain injury. Finally, T-cell activation and MOG-specific T cells are present in the brain of patients with 
ischemic stroke.
Conclusions—Our findings suggest that brain ischemia activates and diversifies T-cell responses locally, which exacerbates 
ischemic brain injury.
Visual Overview—An online visual overview is available for this article.   (Stroke. 2018;49:1471-1478. DOI: 10.1161/
STROKEAHA.118.020203.)
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play a detrimental or protective role on stroke outcomes. Here, 
we investigated the possibility that T-cell responses diversify 
after brain ischemia and that the expanded CNS antigen-spe-
cific T cells could promote brain injury.
Materials and Methods
This article adheres to the American Heart Association Journals 
implementation of the Transparency and Openness Promotion 
Guidelines. Details of materials and experimental procedures are 
available in the online-only Data Supplement. The data that support 
the findings of this study are available from the corresponding author 
on reasonable request.
Human Brain Sections
Human brain sections were obtained from the Department of 
Pathology of the Ohio State University (Columbus, OH) and Banner 
Boswell Medical Center (Sun City, AZ). The ethics consent was 
waived by the institutional review board because autopsy tissues were 
used. Details of human brain sections are given in Methods in the 
online-only Data Supplement.
Mice
We purchased male C57BL/6 (B6, H-2b) and Rag2–/– mice from 
Taconic (Santa Maria, CA). Ovalbumin (OVA) and 2D2 transgenic 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME). 
Details of mice used in this study are given in Methods in the online-
only Data Supplement.
MCAO and Photothrombosis 
Procedure, Neurological Assessment, 
Neuroimaging, and Immunostaining
Adult male 10- to 12-week-old mice were subjected to 60 minutes of 
focal cerebral ischemia produced by transient intraluminal occlusion of 
the middle cerebral artery using a filament as described previously.15–17 
Details of the MCAO and photothrombotic stroke procedures, neuro-
logical assessment, magnetic resonance imaging scan, and immunos-
taining are provided in Methods in the online-only Data Supplement.
Drug Administration
PLX3397 (Selleck Chemicals, Houston, Texas) was prepared and 
given as we described previously. Details are provided in Methods in 
the online-only Data Supplement.
Cell Isolation and Passive Transfer, CFSE Assay, 
Tetramer Staining, Flow Cytometry, and ELISA
Naive-like CD4+ T cells (CD4+CD44lowCD62Lhigh) were isolated from 
pooled splenocytes of WT (wild type), OVA, or 2D2 mice. Cell iso-
lation, cell labeling, cell passive transfer, CFSE (carboxyfluorescein 
succinimidyl ester) assay, tetramer staining, flow cytometry, and 
ELISA were performed as described previously.15–17 Details are given 
in Methods in the online-only Data Supplement.
Statistical Analyses
Details of statistical analyses are given in Methods in the online-only 
Data Supplement. Significance was set at P<0.05. Data are shown as 
means±SEM.
Results
Expansion of T-Cell Reactivity to Neuroantigens 
Occurs in the Brain After Ischemia
Because of the heterogeneity/diversity in T-cell receptor (TCR) 
expression and the inherent technical limitations in measuring 
antigen-specific T-cell response in vivo, limited information 
is currently available on the dynamics of T-cell responses to 
neuroantigens after brain ischemia. Because MOG (myelin 
oligodendrocyte glycoprotein) is a neuroantigen that can be 
rapidly released into the periphery after brain ischemia,13,18 we 
used transgenic mice that harbor a CD4+ MOG35-55-specific 
T-cell clone (2D2). In these mice, the majority of CD4+ T cells 
express a Vα3.2 and Vβ11 TCR, and a large proportion of 
these mice spontaneously develop optic neuritis, suggesting 
preexisting CNS infiltration of autoreactive T cells and base-
line CNS inflammation in these animals.
To measure the anatomic location and timing of T-cell 
changes after stroke, we adoptively transferred naive-like 2D2 
CD4+ T cells (CD4+ CD44low CD62Lhigh Vα3.2+ Vβ11+) pre-
sorted from spleens of naive 2D2 mice that did not have any 
CNS inflammation (Figure 1A). The 2D2 CD4+ T cells were 
transferred into Rag2−/− recipients (lacking T and B cells) 
before MCAO or sham operations. After MCAO or sham 
procedures, 2D2 CD4+ T cells were isolated from spleen and 
brain of Rag2−/− recipient mice (Figure 1B). Thereafter, these 
cells were labeled with CFSE and cocultured with APCs in 
the presence of MOG peptides. Expansion of 2D2 CD4+ T 
cells was measured by dilution of CFSE fluorescence inten-
sity by flow cytometry. Other tested brain antigens included 
NMDA (N-methyl-D-aspartate) receptor NR2A, S-100 
calcium-binding protein β chain (S100β), MAP2 (microtu-
bule-associated protein 2), MBP (myelin basic protein), and 
PLP (proteolipid protein). With the exception of MOG, none 
promoted proliferation of 2D2 CD4+ T cells (Figure I in the 
online-only Data Supplement). Of note, we observed a vigor-
ous proliferation of 2D2 CD4+ T cells in response to MOG35-55 
and other MOG epitopes (MOG91-108 and MOG103-125), espe-
cially in 2D2 CD4+ T cells isolated from brain tissues at day 
4 after MCAO (Figure 1C; Figure I in the online-only Data 
Supplement). In contrast, proliferation of 2D2 CD4+ T cells 
in response to MOG35-55 and additional MOG epitopes was 
seen in 2D2 CD4+ T cells isolated from brain and spleen at 
day 7 after MCAO (Figure 1C).
To confirm the above findings, we measured MOG35-55-, 
MOG91-108-, and MOG103-125-specific T cells via MHC 
(major histocompatibility complex) class II tetramers. At 
day 4 after MCAO, higher frequencies of MOG91-108- and 
MOG103-125-specific T cells were seen in the brains but fewer 
in the spleens of Rag2−/− mice receiving 2D2 CD4+ T cells 
(Figure 1D) or earlier in the brain and spleen, that is, at 
day 2 after MCAO (Figures II and III in the online-only 
Data Supplement). A similar finding was seen in WT mice 
receiving adoptive transfer of naive-like 2D2 CD4+ T cells 
(Figure IV in the online-only Data Supplement). However, 
MOG91-108- and MOG103-125-specific T cells were observed in 
higher numbers both in the spleen and brain at day 7 after 
MCAO (Figure 1D). Immunostaining of brain sections from 
Rag2−/− mice receiving 2D2 CD4+ T cells also showed the 
presence of MOG35-55-, MOG91-108-, and MOG103-125-specific 
T cells at day 4 after MCAO and reperfusion (Figure V in 
the online-only Data Supplement). Together, these results 
suggest that the expanded reactivity of 2D2 T cells to 
brain antigens emerges primarily in the brain after cerebral 
ischemia.
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Antigen-Specific T Cells Are Activated 
Locally in the Brain After Ischemia
Little is known about the anatomic location where T cells are 
activated in response to brain antigens. To define the location 
of T-cell activation and the timing of the autoreactive T-cell 
response after cerebral ischemia, we transferred CFSE-labeled 
MOG35-55-specific CD4+ transgenic (2D2) T cells into Rag2−/− 
recipient mice, followed by 60 minutes of MCAO (Figure 1B). 
2D2 CD4+ T cells proliferated robustly in the ischemic brains 
of Rag2−/− recipient mice (Figure 2A and 2B). In contrast, pro-
liferation of transferred 2D2 CD4+ T cells was weak in spleen, 
lymph nodes, and circulation (Figure 2A and 2B). There was 
Figure 1. Development and expansion of 2D2 T-cell reactivity against neuroantigen epitopes within the ischemic brain. 2D2 CD4+ T cells (CD4+
CD44lowCD62LhighVα3.2+Vβ11+) were sorted from naive 2D2 mice without any sign of central nervous system autoimmune disease and trans-
ferred intravenous (i.v.) into Rag2−/− mice after sham or 60-minute middle cerebral artery occlusion (MCAO) surgery. At day 4 or day 7 after 
surgery, 2D2 CD4+ T cells were reisolated from spleens and brains of Rag2−/− recipients. In the sham group, 2D2 CD4+ T cells were reisolated 
from spleens of Rag2−/− recipients at day 4 after surgery. A, Purity of sorted naive-like 2D2 T cells was validated by fluorescence-activated 
cell sorting (FACS). B, Schematic graph showing the experimental design. C, Flow cytometry plots and cumulative bar graph show CFSE 
(carboxyfluorescein succinimidyl ester) dilution (proliferation) of 2D2 CD4+ T cells in response to in vitro stimulation with OVA, MOG (myelin oli-
godendrocyte glycoprotein)35-55, MOG91-108, and MOG103-125 after coculture for 72 hours with antigen-presenting cells. D, After reisolation at day 
4 or day 7 after surgery, 2D2 CD4+ T cells (Vα3.2+Vβ11+CD4+CD3+) were stained with PE-labeled MHC class II tetramers containing MOG35-55, 
MOG91-108, or MOG103-125 (to identify antigen-specific 2D2 T cells). Representative flow cytometry plots and bar graph show MOG epitope-spe-
cific T cells. All gates were set using fluorescence minus one controls. n=15 per group. Error bars represent SEM. *P<0.05, brain vs spleen.
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an increase of CD25+CD4+ and CD69+CD4+ 2D2 T cells in the 
brain but not in the spleen, lymph nodes, and circulation at day 
4 after reperfusion (Figure 2C and 2D). These data suggest 
that 2D2 CD4+ T cells are activated primarily in the brain at 
day 4 after reperfusion.
Lastly, we found a dramatic increase of TCRvβ usage in 
brain-infiltrating 2D2 CD4+ T cells (Figure VI in the online-
only Data Supplement). In particular, the usage of TCRvβ 
5.1, 5.2, 13, and 3 was significantly higher (Figure VI in the 
online-only Data Supplement), suggesting the presence of 
clonal expansions in brain-infiltrating 2D2 CD4+ T cells after 
ischemia. Together, these results suggest that the entry of 2D2 
CD4+ T cells into the ischemic brain is not stochastic but anti-
gen driven.
2D2 T Cells Are Activated by Local APCs 
in the Brain After Cerebral Ischemia
Although CD4+ T cells are activated by MHC II presenta-
tion of epitopes by APCs, recent data also suggest alter-
native pathways that may not depend on MHC II.14,19 To 
determine whether MHC II/TCR interaction is required for 
brain ischemia-induced expansion of 2D2 CD4+ T cells to 
MOG epitopes, we used MHC II knockout mice (H2-Ab1–
/–H2-Aa–/–H2-Eb1–/–H2-Eb2–/–H2-Ea–/– mice). We transferred 
2D2 CD4+ T cells into Rag2−/−MHC II–/– mice (Figure 3A). 
Although the transferred 2D2 CD4+ T cells were unable to 
be maintained in the periphery because of lack of MHC II, 
as reported,19,20 these cells survived for at least a week in 
Rag2−/−MHC II–/– recipients (Figure 3B and 3C). The occur-
rence of the new reactivity against additional MOG epit-
opes (MOG91-108 and MOG103-125) was reduced in 2D2 T cells 
after transfer into Rag2−/−MHC II–/– mice. A similar find-
ing was seen in MHC II–/– mice receiving adoptive transfer 
of 2D2 CD4+ T cells (Figure VII in the online-only Data 
Supplement). Together, these results suggest the requirement 
of MHC class II/TCR interaction for the expansion of T cells 
to neuroantigens (Figure 3B and 3C).
Because activation and proliferation of 2D2 CD4+ T cells 
is predominantly initiated in the brain but not peripheral 
sites after ischemia, we determined which APCs presented 
brain antigens to 2D2 CD4+ T cells. Microglia-like cells had 
the highest expression of MHC II in the brain of Rag2−/− 
mice at day 4 after MCAO (Figure VIII in the online-only 
Data Supplement). Also, among the cells positive for MHC 
II and MOG35-55, microglia-like cells had the highest num-
bers (Figure VIII in the online-only Data Supplement). 
Finally, some 2D2 CD4+ T cells were in close proximity to 
Iba1+ cells in brain sections from Rag2−/− mice at day 4 after 
MCAO (Figure IX in the online-only Data Supplement), 
and MOG35-55 colocalized with Iba1+ cells (Figure X in the 
online-only Data Supplement), suggesting that MOG may 
be processed by these cells and presented to the infiltrating 
2D2 CD4+ T cells.
Next, CFSE-labeled 2D2 CD4+ T cells were cocul-
tured with purified microglia-like cells (CD11b+CD45int), 
macrophages (CD11b+CD45hi F4/80+), or dendritic cells 
(CD11c+CD45hiF4/80−) in either presence or absence (to 
assess endogenous presentation) of MOG35-55 peptide (Figure 
VIII in the online-only Data Supplement). In the presence of 
exogenous peptide, all 3 populations could induce prolifera-
tion of 2D2 CD4+ T cells. Without added peptide, all 3 APC 
populations also induced proliferation of 2D2 CD4+ T cells. 
However, only microglia-like cells induced robust prolifera-
tion of 2D2 CD4+ T cells. In contrast, the proliferation of 2D2 
CD4+ T cells induced by either macrophage or dendritic cells 
was to a lesser extent (Figure VIII in the online-only Data 
Figure 2. Activation and proliferation of 2D2 T cells occur primarily in the brain after brain ischemia. A and B, 2D2 CD4+ T cells were 
isolated from splenocytes of 2D2 mice without any sign of central nervous system autoimmune disease and adoptively transferred into 
Rag2−/− mice followed by sham or 60-minute middle cerebral artery occlusion (MCAO) procedures. At day 4 after sham or MCAO, 2D2 
CD4+ T cells were reisolated from spleens, lymph nodes (LNs), peripheral blood, and brains of Rag2−/− recipients. Reactivity of 2D2 CD4+ 
T cells was assessed by CFSE assay. Bar graph shows quantification of 2D2 CD4+ T-cell reactivity. C and D, Flow cytometry plots and 
quantification of CD4+ cell activation (CD25+CD4+, CD69+CD4+) in single-cell suspensions reisolated from spleens, LNs, circulating blood, 
and brains of passively transferred mice subjected to MCAO. All gates were set using fluorescence minus one controls. n=10 per group. 
Error bars represent SEM. **P<0.01, brain vs spleen, LN, or circulation.
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Supplement). These data demonstrate a strong capacity of 
microglia to present brain antigen peptides to T cells.
We also depleted microglia using PLX3397—an inhibitor 
of colony stimulating factor 1 receptor, which specifically 
depletes microglia.21 We found that reduction of microglia 
abolished the increase of MOG91-108- or MOG103-125-specific 
2D2 T cells (Figure VIII in the online-only Data Supplement). 
These data imply that brain-resident microglia are key APCs 
for the expansion of 2D2 T-cell reactivity to brain antigens in 
the ischemic brain.
Diversified T-Cell Responses Exacerbate 
Ischemic Brain Injury
To evaluate the impact of brain ischemia-induced diversifica-
tion of T-cell response on stroke outcomes, we used 2D2 CD4+ 
T cells from spleens of sham 2D2 mice and antigen-experi-
enced 2D2 CD4+ T cells from spleens of 2D2 mice at day 7 
after MCAO or photothrombosis. We transferred WT, OVA-
specific, 2D2, or antigen-experienced 2D2 CD4+ T cells into 
Rag2−/− mice before MCAO or photothrombosis (Figure 4A). 
More severe neurodeficits and significantly larger infarct 
volumes were seen in Rag2−/− mice receiving antigen-expe-
rienced 2D2 CD4+ T cells as compared with WT mice, OVA-
specific, or 2D2 CD4+ T cells from naive 2D2 mice, starting at 
day 4 after MCAO (Figure 4B) or at day 7 after photothrom-
botic stroke (Figure 4C). Increased neurodeficits and brain 
infarction volumes persisted at least until day 7 after MCAO 
(Figure 4B) or photothrombotic stroke (Figure 4C). Thus, 
brain ischemia-induced diversification of T-cell responses has 
a detrimental impact on ischemic brain injury.
To visualize brain-infiltrating antigen-experienced 2D2 T 
cells, we noninvasively tracked 2D2 CD4+ T cells by adoptive 
transfer of Molday ION Rhodamine B-labeled cells into Rag2−/− 
mice before MCAO. After reperfusion, we found increased 
hypointensive spots in Rag2−/− mice receiving antigen-experi-
enced 2D2 CD4+ T cells (Figure 5A). In addition, significantly 
increased levels of IFN-γ (interferon gamma), interleukin (IL)-
17, TNF-α (tumor necrosis factor-α), IL-1β, and IL-6 were 
seen in brain homogenates of Rag2−/− mice receiving antigen-
experienced 2D2 CD4+ T cells (Figure 5B). The analysis of Th1 
and Th17 responses in Rag2−/− mice receiving antigen-experi-
enced 2D2 CD4+ T cells showed significantly higher numbers 
of brain-infiltrating CD4+, IFN-γ+ CD4+, and IL-17+CD4+ T 
cells in Rag2−/− mice receiving antigen-experienced 2D2 CD4+ 
T cells versus WT, OVA-specific, or naive 2D2 CD4+ T cells 
(Figure 5C), suggesting that antigen-experienced T cells exac-
erbate brain inflammation after cerebral ischemia.
These results imply that CD4+ T cells enter the brain and 
become activated after ischemia, where multiple brain anti-
gens presented by local APCs diversify the T-cell responses 
that exacerbate brain infarction.
Presence of Neuroantigen-Specific T Cells 
in the Brain of Patients With Stroke
Brain slices from patients with acute middle cerebral artery 
ischemic stroke showed that CD4+ T cells infiltrated the infarct 
and peri-infarct areas. Some of these cells resided in close 
vicinity to ischemic neurons (Figure XI in the online-only 
Data Supplement). Of interest, MOG35-55-, MOG91-108-, and 
MOG103-125-specific CD4+ T cells were seen in the peri-infarct 
Figure 3. The occurrence of new reactiv-
ity of 2D2 T cells depends on MHC II. 
2D2 CD4+ T cells were sorted from spleen 
of 2D2 mice without central nervous 
system autoimmune disease, and trans-
ferred intravenous (i.v.) into Rag2−/− or 
Rag2−/−MHC II−/− recipient mice before 
60 min of middle cerebral artery occlu-
sion (MCAO) surgery. A, Schematic graph 
showing the experimental design. B, At 
day 4 or day 7 after reperfusion, 2D2 
CD4+ T cells were reisolated from brains 
of Rag2−/− or Rag2−/−MHC II−/− mice and 
then stained with PE-labeled tetramers 
containing MOG (myelin oligodendrocyte 
glycoprotein)35-55, MOG91-108, or MOG103-125 
epitopes. Flow cytometry plots show 
MOG epitope-specific 2D2 CD4+ T cells. 
All gates were set using fluorescence 
minus one controls. C, Bar graph shows 
quantification of surface expression of 
antigen-specific T-cell receptors at day 
4 and day 7 after reperfusion. n=15 per 
group. Error bars represent SEM. *P<0.05, 
**P<0.01.
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areas (Figure XI in the online-only Data Supplement), indi-
cating the presence of neuroantigen-specific CD4+ T cells in 
human stroke lesions.
Discussion
In this study, we precisely tracked the myelin-reactive T cells 
with tetramers and revealed that the antigen spectrum was 
expanded with the progression of ischemia-induced brain 
injury. To our knowledge, this study provides the first defini-
tive evidence on the activation of CD4+ T cells, which subse-
quently acquire new reactivity within the brain.
The finding of the 2D2 T-cell specificities to MOG91-108 
and MOG103-125 suggests the expansion of T-cell reactivity 
against new brain antigen epitopes after stroke. This finding 
is supported by a previous study showing that T cells bear-
ing the same Vα and Vβ genes can have different antigen 
specificity.22 However, one might argue that new specificities 
could derive from carryover clones from the 2D2 donors or 
derive from MOG35-55-specific clones with cross-reactivity 
to the other 2 MOG peptides. Yet, MOG35-55-specific T cells 
isolated from naive 2D2 mice only had minimal reaction to 
MOG91-108 and MOG103-125, suggesting that MOG35-55-specific 
2D2 T cells were specific, as also supported by the diver-
sity of Vβ expression that supports the expansion of T-cell 
response in the poststroke environment. One recent study 
showed that stroke induced a secondary, dynamic autoim-
mune response to neuronal antigens, maintained through 10 
days in both lymph nodes and spleen.9 In line with those find-
ings, our results suggest that the expansion of T-cell response 
could occur both in the periphery and CNS after ischemia. 
However, the activation and proliferation of naive-like 2D2 
T cells were more prominent in the brain than in peripheral 
lymphoid organs, suggesting that the expansion of T cells 
could be initiated in the brain, possibly because of the stroke-
induced environment. In support of this, another report sug-
gested that the expansion of T-cell clones may occur first in 
the ischemic brain and subsequently in secondary lymphoid 
organs.23 Thus, activation of T cells would occur predomi-
nantly in the CNS after stroke.
The findings of 2D2 T cells reactive to other MOG epitopes 
in the ischemic brain and its dependence on MHC II impli-
cate antigen presentation. In the context of stroke, the CNS 
harbors both peripheral APCs homing into the ischemic brain 
and CNS-resident APCs. Our findings of higher numbers of 
MHC II-expressing microglia-like cells colocalizing with 
MOG peptide, together with their stronger capacity to pres-
ent endogenous MOG, suggest a major role of microglia in 
the expansion of 2D2 T cells. Indeed, depletion of microglia 
ablated occurrence of new reactivity to additional MOG epit-
opes after stroke. Past studies reported the expression of MHC 
II on microglia on their activation and myelin debris phagocy-
tosed by microglia in neuroinflammatory conditions.24–26 More 
recent findings suggest that resident microglia are the first 
responders to brain ischemia and that phagocytosis of neural 
debris by microglia takes place in the early stages of stroke, 
before the arrival of infiltrating peripheral macrophages.26,27 
Of note, microglia possess multiple functions, including anti-
gen presentation and production of inflammatory factors, 
Figure 4. Diversified T-cell responses exacerbate neurodeficits and brain infarction. CD4+ T cells (CD4+CD44lowCD62Lhigh) were obtained 
from spleens of wild-type mice (WT→Rag2−/−) and OVA mice (OVA→Rag2−/−) at day 7 after sham surgery, naive 2D2 mice (naive 
2D2→Rag2−/−) at day 7 after sham surgery, or 2D2 mice at day 7 after middle cerebral artery occlusion (MCAO) or photothrombosis (anti-
gen [Ag]-experienced 2D2→Rag2−/−). These T cells were injected intravenous (i.v.) into Rag2−/− recipients and followed by 60 min of MCAO 
or photothrombotic stroke procedures at 24 hours after injection. A, Schematic graph showing the experimental design. B, The neurologi-
cal deficit scores (mNSS) were assessed in different groups at the indicated days after MCAO (B) or photothrombosis (C). 7T magnetic 
resonance imaging shows brain lesions in different groups at day 4 after MCAO (B) or photothrombosis (C). Cumulative results show 
quantifications of lesion volume. n=12 mice per group. *P<0.05, **P<0.01.
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which enable microglia to interact with several cell types 
other than T cells. These diverse features suggest a profound 
role of microglia in brain injury depending on the settings of 
animal models and disease conditions.
Some have suggested that myelin-reactive lymphocytes 
are detrimental in rodent stroke models,13 and clinical studies 
have linked autoreactive T-cell responses to worsened out-
comes in patients with stroke.28 Our study suggests a series 
of events in which antigen presentation promotes T-cell 
expansion that fuels focal inflammation during the evolution 
of brain infarction and neurodeficit. This raises the possibil-
ity that preexisting or newly emerged brain antigen-specific 
T cells could favor brain injury in patients with first-ever or 
recurrent stroke attacks, implying possible therapeutic block-
ade of the recruitment and activation of T cells to attenuate 
ischemic brain injury.
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